The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Mexican President Claudia Sheinbaum expressed her resolve to maintain composure while awaiting the United States' decision ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
An executive order designating cartels as terrorist organizations will expand prosecutors' jurisdictions, affect relations ...
According to the company, the sNDA is supported by findings from the Phase II LITESPARK ... 1 “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and ...
PALO ALTO, Calif. - Scilex Holding Company (NASDAQ:SCLX), a $77.5 million market cap company known for its focus on non-opioid pain management products, reported that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback